The Study Of Albumin As A Drug Carrier

Albumin is the most common protein carrier in the field of drug delivery.It has the characteristics of non-toxic,non-immune,easy to purify,soluble in water,and easy to inject.Based on its advantages of high biocompatibility and biodegradability,albumin has become the best candidate for drug carriers,and albumin is often made into nanoparticles for use in the field of drug carriers.Compared with other drug carriers,nanoparticles have a larger specific surface area and a smaller particle size,generally located at 10-1000 nm.Due to their unique quantum properties and the ability to adsorb and load other compounds,nanoparticles are extremely popular in the field of medical treatment.Based on the prior art,most of the drug carriers are designed for the purpose of drug loading,and the carrier itself lacks drug activity.We conducted the research in this paper.In this paper,bovine serum albumin?BSA?was used as the main raw material,and the cinnamon extract?CA?with anti-cancer activity was selected as the drug molecule,the CA was modified.CA reacted with anthranilyl hydrazide?AH?to obtain a cinnamaldehyde derivative?CAH?with the characteristic hydrazone bond,which could be broken in the weak acid environment of cancer cells to release CA.CAH was used as a drug active molecule to bind to the active site of BSA surface?the carboxyl group on the amino acid residue?.BSA-CAH NPs were prepared by desolvation.The preparation route was optimized to obtain the best preparation conditions:H₂O:Et OH=6:1,m_?BSA?:m_?CAH?=24:1,reaction temperature was 25?,non-ultrasonic environment,reaction time was 3 h.A series of tests were performed to characterize the prepared product.Infrared spectroscopy and nuclear magnetic resonance spectroscopy were used to characterize the structure of CAH.The p H-sensitivity of CAH was determined by colorimetry and ultraviolet spectrophotometry.CAH would spontaneously break down and release CA with anti-cancer activity in weakly acidic?p H4.0-5.0?environments.A series of characterizations were performed on the prepared albumin nanoparticles,such as Zeta potential test,GPC test,atomic force microscope test and transmission electron microscope test.The isoelectric point of BSA-CAH NPs was higher than that of BSA,and about 56 CAH could combine with 1 BSA.The encapsulation rate was 36.615 mg/g,and the release rate of CA was 96.6%in vitro simulation experiment.The nanoparticles were in the form of round particles with well-dispersed sizes,the particle size was 156nm,and PDI was 0.313.In order to determine the structural changes of bovine serum albumin before and after preparation,circular dichroism spectrum test,fluorescence test,ultraviolet spectrophotometry test and solid-state nuclear magnetic test were performed to analyze the changes of protein secondary structure.Finally,the cell uptake of BSA-CAH NPs was observed and the inhibition rate of different cancer cells was explored.Although the prepared BSA-CAH NPs nanoparticles had a certain inhibition rate for different cancer cells,they had obvious effects on some of them.BSA-CAH NPs can be used for the targeted treatment of human laryngeal squamous cell carcinoma.The innovation of this paper:We chose a drug molecule CA with anti-cancer ability to react with AH to obtain CAH with hydrazone bond.The hydrazone bond can be broken under weakly acidic and strong alkaline conditions and release CA with drug activity.By desolvation method,CAH and BSA are used as a bridge to prepare a special anti-cancer activity albumin nanoparticle drug carrier.The covalently bound CAH can achieve the effect of CA in the unique weak acid internal environment of tumors.Release,p H-sensitive,it has certain anti-cancer ability,and the preparation method is easy to realize in the laboratory,non-toxic,degradable,and has extremely high application value.